NurExone's Exosome Therapy Shows Promise in Optic Nerve Injury Preclinical Study
Event summary
- NurExone's naïve exosomes and ExoPTEN demonstrated measurable retinal activity in optic nerve injury models, with ExoPTEN showing statistically significant improvement.
- The study, conducted in collaboration with Prof. Ygal Rotenstreich’s team at the Goldschleger Eye Institute, supports advancing the program to larger-animal studies.
- ExoPTEN-treated eyes showed a statistically significant improvement in retinal response compared with the control group (p = 0.04).
- The company plans to initiate a rabbit model study, subject to final protocol development, funding, and regulatory approvals.
The big picture
NurExone's positive preclinical results in optic nerve injury models underscore the potential of exosome-based therapies in addressing unmet medical needs in vision-threatening conditions. The company's strategic focus on both spinal cord and optic nerve injuries positions it at the forefront of regenerative medicine, though the path from preclinical success to commercialization remains challenging. The planned larger-animal studies will be critical in validating the therapeutic potential of ExoPTEN and advancing it toward human clinical evaluation.
What we're watching
- Clinical Translation
- Whether the preclinical success of ExoPTEN in optic nerve injury models will translate to similar results in larger-animal studies and eventually human trials.
- Regulatory Pathway
- The pace at which NurExone can secure regulatory approvals for its planned rabbit model study and subsequent clinical evaluations.
- Commercial Strategy
- How NurExone will leverage its exosome-based therapies for other indications, given its broader development and commercialization plans.
Related topics
